

Contents

Preface *xiii*

Preface from the Volume Editors *xv*

Part I How mRNA Vaccines Work *1*

1 A Historical Overview on mRNA Vaccine Development *3*

Rein Verbeke, Miffy H.Y. Cheng, and Pieter R. Cullis

- 1.1 Introduction *3*
- 1.2 The Path of mRNA as an Unstable and Toxic Product to a New Class of Medicine *5*
 - 1.2.1 The Discovery and *In Vitro* Production of mRNA *5*
 - 1.2.2 The Inflammatory Nature of mRNA *7*
- 1.3 How Studying Lipid Bilayer Structures in Cell Membranes Gave Rise to the Eventual Development of Lipid Nanoparticles for RNA Delivery *8*
 - 1.3.1 From Biological Cell Membranes to Liposomal Drugs *8*
 - 1.3.2 Ionizable Lipid Nanoparticles for Systemic Delivery of Nucleic Acids *10*
- 1.4 The Journey of Developing Clinical mRNA Vaccines *12*
- 1.5 Concluding Remarks *14*
References *15*

2 Immune Responses to mRNA Vaccine *29*

Jean-Yves Exposito, Claire Monge, Danielle C. Arruda, and Bernard Verrier

- 2.1 Introduction *29*
- 2.2 Innate Sensing of RNA Molecules *30*
- 2.3 Innate Immune Response to mRNA Vaccines *32*
 - 2.3.1 Innate Immune Response in Humans *33*
 - 2.3.2 Tissue Innate Immune Response in Mice *34*
- 2.4 mRNA Design and Innate Immunity *35*
 - 2.4.1 Cap *35*
 - 2.4.2 Untranslated Regions *37*

2.4.3	Poly(A)	39
2.4.4	Coding Sequence	41
2.5	Optimization and Production of mRNA for an Adequate Innate Immune Response	42
2.5.1	IVT Production	42
2.5.2	Posttranscriptional Modification	44
2.5.3	Purification	45
2.6	mRNA Delivery Systems and Immune Response: The Role of Formulation Composition	45
2.7	Concluding Remarks and Perspectives	51
	Acknowledgments	54
	References	54

3 Modified or Unmodified mRNA Vaccines? – The Biochemistry of Pseudouridine and mRNA Pseudouridylation 69

Pedro Morais and Yi-Tao Yu

3.1	Pseudouridine (Ψ): The Fifth Nucleoside	69
3.2	RNA Pseudouridylation Mechanism	70
3.2.1	Naturally Occurring RNA Pseudouridylation	71
3.2.1.1	RNA-independent Pseudouridylation Catalyzed by PUS Enzymes	71
3.2.1.2	RNA-dependent Pseudouridylation Catalyzed by Box H/ACA snoRNP	71
3.2.2	Artificially Introduced RNA Pseudouridylation	73
3.2.2.1	Targeted Pseudouridylation of RNA Using Artificial Guide RNAs	73
3.2.2.2	Incorporation of Ψ During <i>In Vitro</i> Transcription of RNA	74
3.3	Ψ detection in RNA	75
3.3.1	Indirect Ψ Sequencing Methods	76
3.3.2	Direct Ψ Sequencing Methods	76
3.4	Impact of Ψ in Pre-mRNA Splicing and Protein Translation	77
3.4.1	Effect of Ψ in snRNA and Pre-mRNA on Pre-mRNA Splicing	77
3.4.2	Effect of Ψ in rRNA and tRNA on Protein Translation	77
3.4.3	Effect of mRNA Pseudouridylation on Nonsense Suppression	78
3.4.4	Effect of mRNA Pseudouridylation on the Coding Specificity of Sense Codons	80
3.5	Ψ and the Immune System	80
3.6	Pseudouridylated Versus Unmodified mRNA Vaccines	82
3.6.1	Ψ Successor: N1-methyl-Ψ	82
3.6.2	Nucleoside-modified COVID-19 mRNA Vaccines	84
3.6.3	Unmodified mRNA COVID-19 vaccines	85
3.6.4	Cancer mRNA Vaccines	89
3.7	Conclusions	90
	Acknowledgments	92
	Conflict of Interest	92
	References	92

4	Self-Replicating RNA Viruses for Vaccine Development	109
	<i>Kenneth Lundstrom</i>	
4.1	Introduction	109
4.2	Expression Systems For Self-Replicating RNA Viruses	109
4.3	Vaccines Against Infectious Diseases	113
4.4	Vaccines Against Cancers	130
4.4.1	Reporter Gene Expression	131
4.4.2	Tumor-associated Antigens	131
4.4.3	Cytotoxic and Anti-tumor Genes	139
4.4.4	Immunostimulatory Genes	139
4.4.5	Oncolytic Viruses	140
4.5	Conclusions and Future Aspects	143
	References	144
5	Circular RNA Therapeutics and Vaccines	161
	<i>Xiang Liu and Guizhi Zhu</i>	
5.1	Introduction	161
5.2	The Biogenesis and Physiological Functions of Natural circRNA	162
5.2.1	The Biogenesis of Natural circRNA	162
5.2.2	The Physiological Functions of Natural circRNA	162
5.3	The Design and Synthesis of Synthetic circRNA	163
5.3.1	Design Considerations of Synthetic circRNAs for Vaccines	163
5.3.2	Approaches to circRNA Synthesis	164
5.4	The Applications of Synthetic circRNA as Novel Therapeutics and Vaccines	168
5.5	The Delivery Systems of Synthetic circRNA	170
5.6	Conclusion	170
	References	171
6	Good Manufacturing Practices and Upscaling of mRNA Vaccine Production	177
	<i>Eleni Stamoula, Theofanis Vavilis, Ioannis Dardalas, and Georgios Papazisis</i>	
6.1	Introduction	177
6.2	Plasmid Production	178
6.3	Considerations of <i>In Vitro</i> Transcription Stage	180
6.3.1	The <i>In Vitro</i> Transcription Reaction	180
6.3.2	Purification of the <i>In Vitro</i> Transcribed RNA	181
6.4	Considerations of Lipid Nanoparticles (LNPs)	185
6.4.1	Synthesis of LNP and mRNA Encapsulation	185
6.4.2	Scaling Up Production of LNPs to Industrial Standards	186
6.5	Considerations of Fill-to-Finish and Storage	186
6.6	mRNA and mRNA–LNP Critical Quality Attribute Analysis	187
6.7	General Remarks and Further Considerations	189
	References	191

7	mRNA Vaccination for Induction of Immune Tolerance Against Autoimmune Disease	201
	<i>Mark C. Gissler, Felix S.R. Picard, Timoteo Marchini, Holger Winkels, and Dennis Wolf</i>	
7.1	Role of Adaptive Immune Cells in Autoimmunity and Tolerance	201
7.1.1	Development of the Adaptive Immune System – Defining the Boundaries of Autoimmunity	201
7.1.2	Diversity of Adaptive Immunity	201
7.1.3	Antigen-Specific T Cells	202
7.1.4	T-cell Phenotypes and Functions	203
7.1.4.1	CD4 ⁺ T Cells	203
7.1.4.2	CD8 ⁺ T Cells	204
7.1.5	Role of B Cells and Autoantibodies	204
7.1.5.1	Development of B Cells	204
7.1.5.2	Somatic Hypermutations in B Cells – Refining High-Affinity Antibodies	205
7.1.5.3	Noncanonical Functions of B Cells	206
7.1.6	Autoimmune Diseases – Break of Tolerance Against Self-antigens	206
7.1.7	Immunomodulation of Autoimmune Diseases	207
7.1.7.1	Tolerogenic Vaccination to Dampen MHC-II-Dependent Autoimmunity	208
7.2	Atherosclerosis – An Unprecedented Autoimmune Disease	208
7.2.1	Autoimmune Component of Atherosclerosis	208
7.2.1.1	Role of Antigen-Specific T-Helper Cells in Atherosclerosis	209
7.2.1.2	B Cells and Autoantibodies in Atherosclerosis	209
7.2.2	Established Autoantigens in Atherosclerosis	210
7.2.2.1	LDL-C and ApoB	210
7.2.2.2	Heat-Shock Proteins	211
7.2.2.3	Beta-2-Glycoprotein I	211
7.2.2.4	Virus-Derived Antigens	211
7.2.3	Mechanism of Tolerogenic Peptide Vaccination in Atherosclerosis	212
7.2.4	Alternative Immunomodulation Against Cardiovascular Disease (CVD) Autoimmunity	212
7.2.4.1	DNA and mRNA Vaccination	212
7.2.4.2	Immunotherapy with Immunoglobulins	214
7.2.4.3	TCR/CAR T-cell Immunotherapy	215
7.3	The Autoimmune Component of MS	215
7.3.1	Pathophysiology of MS	215
7.3.2	Role of Antigen-Specific Immunity in MS	215
7.3.3	Mimicking MS by EAE Model	216
7.3.4	Vaccination Approaches to Prevent EAE	216
7.3.4.1	mRNA-Based Tolerogenic Vaccination Against EAE	217
7.4	Framework and Rationale for Future mRNA-Based Peptide Vaccination Strategies in Autoimmune Diseases	218

- 7.4.1 Evidence for mRNA Vaccination to Induce Tolerance in Animal Models 219
- 7.4.2 Limitations of Traditional Peptide Vaccination 220
- 7.4.3 Challenges of Future Vaccination Strategies 221
 - 7.4.3.1 Antigen Targets and MHC Variability 221
 - 7.4.3.2 Clinically Applicable Adjuvants and Routes of Administration 222
 - 7.4.3.3 Effectiveness and Safety of Peptide Vaccination 223
 - 7.4.3.4 Requirement of Clinical Biomarkers 223
- 7.4.4 Outlook: Chances of mRNA-Based Approaches in Future Clinical Immunomodulation in Allergy 224
- List of Abbreviations 227
- Acknowledgements 228
- Conflict of Interest 228
- References 228

Part II Recent Progress in Vaccine Research and Development 241

- 8 Design and Development of mRNA Vaccines to Combat the COVID-19 Pandemic 243**
Istvan Tombacz
 - 8.1 Introduction 243
 - 8.2 SARS-CoV-2 Vaccine Design 244
 - 8.3 Development of SARS-CoV-2 mRNA Vaccines 247
 - 8.3.1 mRNA-1273 – Moderna 247
 - 8.3.2 BNT162b2 – Pfizer/BioNTech 248
 - 8.4 Other SARS-CoV-2 mRNA Vaccines Developments 249
 - 8.4.1 CVnCoV – CureVac 249
 - 8.4.2 Additional mRNA-based SARS-CoV-2 Vaccines Evaluated in Clinical Trials 250
 - 8.5 Booster Immunizations and Variants of Concern 251
 - 8.6 Future Directions 252
 - References 253
- 9 mRNA Vaccines for HIV-1 259**
Paolo Lusso
 - 9.1 Introduction 259
 - 9.1.1 A Long and Winding Road: 40 Years and Counting 259
 - 9.1.2 A Very High Bar: Failure of Traditional Approaches 260
 - 9.1.3 A New Era: An HIV-1 Vaccine Is Feasible 260
 - 9.2 Strategies for HIV-1 Vaccine Design 261
 - 9.2.1 Main Strategies 261
 - 9.2.1.1 Lineage-Based Vaccines 261

9.2.1.2	Mutation-Guided Vaccines	262
9.2.1.3	Structure-Based Vaccines	262
9.2.1.4	Epitope-Based Vaccines	262
9.2.1.5	Combination Strategies	263
9.3	mRNA-Based HIV-1 Vaccines	263
9.3.1	Why mRNA?	263
9.3.2	Key Technological Breakthroughs	265
9.3.3	Main Platforms for mRNA-Based HIV-1 Vaccines	265
9.3.3.1	mRNA-Transduced Dendritic Cells	267
9.3.3.2	Direct <i>In Vivo</i> mRNA Delivery	267
9.3.3.3	The Rise of the LNPs	269
9.3.3.4	Self-Amplifying mRNA	270
9.4	Recent Advances in HIV-1 mRNA Vaccine Design	271
9.4.1	The Medium Is Not the Message	271
9.4.2	Specific Approaches	271
9.4.2.1	A VLP-Forming <i>env-gag</i> mRNA Platform	272
9.4.2.2	Self-Assembling Nanoparticles	274
9.4.2.3	Engineered Germline-Engaging gp120 Cores	274
9.5	The Future	275
9.5.1	Room for Improvement	276
9.5.1.1	Mucosal Delivery and Other Alternative Routes	276
9.5.1.2	Slow Delivery	276
9.5.1.3	Env-Gag VLP Optimization	277
9.5.1.4	Multiple-Array Antigen Presentation	277
9.5.1.5	Supplemental Adjuvants	278
9.5.1.6	Combination of mRNA with Other Platforms	278
9.6	Concluding Remarks	279
	Acknowledgment	279
	References	279
10	mRNA Vaccines Against Tick-borne Diseases	285
	<i>Gunjan Arora and Erol Fikrig</i>	
10.1	Introduction	285
10.2	Vector-borne Diseases	285
10.3	Tick-borne Diseases	286
10.4	Tick Saliva Antigens as Vaccine Candidates	286
10.5	Vaccines Targeting Pathogens That Cause Tick-borne Diseases	288
10.6	mRNA Vaccines	288
10.7	An mRNA Vaccine Against Ticks	289
10.8	Powassan Vaccine	291
10.9	RNA Vaccine Against Crimean–Congo Hemorrhagic Fever Virus	291
10.10	Conclusions	292
	References	293

11	mRNA Vaccines for Malaria and Other Parasitic Pathogens	303
	<i>Leroy Versteeg and Jeroen Pollet</i>	
11.1	The Global Burden of Parasitic Pathogens	303
11.2	Challenges of Vaccine Development Against Parasitic Pathogens	305
11.3	mRNA Technology to Accelerate the Development of Advanced Next-Generation Vaccines	307
11.4	Accessibility, Manufacturing Capacity, and Logistics of mRNA for Low- and Mid-Income Countries	308
11.5	Published Data on mRNA Vaccines Against Parasitic Pathogens	311
11.5.1	Malaria	311
11.5.2	Toxoplasmosis	314
11.5.3	Leishmaniasis	315
11.5.4	Chagas Disease	316
11.5.5	Helminths	317
11.6	Conclusions and Prospects	317
	References	318
12	Current State of mRNA Vaccine Development Against <i>Mycobacterium tuberculosis</i>	325
	<i>Ilke Aernout, Rein Verbeke, Stefaan C. De Smedt, Francis Impens, and Ine Lentacker</i>	
12.1	Introduction	325
12.2	Immune Responses Responsible for Protective Immunity Against <i>Mycobacterium tuberculosis</i>	326
12.3	Suitability and Advantages of an mRNA Vaccine Platform Against <i>Mycobacterium tuberculosis</i>	328
12.4	mRNA TB Vaccines in (Pre-)clinical Development	330
	Acknowledgments	332
	References	332
13	Cancer Vaccines Based on mRNA: Hype or Hope?	337
	<i>Wout de Mey, Dorien Autaers, Giada Bertazzon, Arthur Esprit, Marta Marco Aragon, Lorenzo Franceschini, and Karine Breckpot</i>	
13.1	Tumors: Setting the Scene for Cancer Immunotherapy	337
13.2	Cancer Vaccination	339
13.3	Vaccine Development Rules: A Brief Overview of Lessons Learned	342
13.3.1	Use Multiple and Highly Immunogenic Tumor-Specific Antigens	342
13.3.2	Use a Potent Adjuvant	343
13.3.3	Use an Efficacious, Flexible, Safe, and Preferably Low-Cost Vaccine Vector	345
13.3.4	Choose the Best Route of Delivery	346
13.3.5	Incorporate Strategies to Subdue Tumor-Mediated Immunosuppression	349
13.4	mRNA: From Discovery to Application in Vaccinology	351

xii | *Contents*

13.5	mRNA Manufacturing and Design	353
13.6	mRNA Delivery and Formulation	358
13.7	Controlling the Innate Immune Sensing of mRNA	362
13.8	Adjuvants for mRNA-Based Vaccines	366
13.9	Clinical Application	368
13.10	Conclusion	373
	References	374

Index	401
--------------	------------